AbbVie Inc. and ADMA Biologics, Inc.: SG&A Spending Patterns Compared

SG&A Spending Patterns: A Tale of Two Biopharma Giants

In the dynamic world of biopharmaceuticals, understanding spending patterns can reveal much about a company's strategic priorities. Over the past decade, AbbVie Inc. and ADMA Biologics, Inc. have demonstrated contrasting approaches in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, AbbVie's SG&A expenses have consistently dwarfed those of ADMA, with AbbVie spending nearly 200 times more on average. This reflects AbbVie's expansive market reach and robust operational scale. Notably, AbbVie's SG&A expenses peaked in 2022, reaching approximately 15.3 billion, a 98% increase from 2016. Meanwhile, ADMA's spending, though modest, has shown a steady upward trend, growing by over 1,100% from 2014 to 2023. This growth underscores ADMA's strategic investments in scaling operations and market presence. As these companies navigate the competitive landscape, their SG&A spending patterns offer a window into their evolving business strategies.